

Please complete and return to your Working Groups Officer / Coordinator (jpena@escardio.org / cgomez@escardio.org)

Every **even year** in **July** (before the ESC Congress)

Every **odd year** in **September** (after the ESC Congress)

Identification

Working Group on: Cardiovascular Pharmacology and Drug Therapy

Nucleus Composition

Chairperson:	Keld Per Kjeldsen, Denmark
Vice-chairperson	Stefan Agewall, Norway
Past Chairperson	Luis Miguel Ruilope, Spain
Treasurer	Giuseppe Rosano, Italy
Secretary	Sven Wassmann, Germany/Basil S Lewis, Israel
Web and Communication Officer	Harald Schmidt, The Netherlands
Nucleus Members	1- Heinz Drexel, Austria
	2- Basil S. Lewis, Israel
	3- Atul Pathak, France
	4- Juan Tamargo, Spain
	5- Christian Torp-Pedersen, Denmark
Ex-Officio Members	Dan Atar, Norway
.....	Maria Angeles Alonso Garcia, Spain
.....	Faiez Zannad, France

Elections: None

Chair / Organisation committee
Date
Place
Position(s) to be occupied
Names of Candidates
Number of voting delegates (WG members)
Number of registered participants (votes)
Results

Please complete and return to your Working Groups Officer / Coordinator (jpena@escardio.org / cgomez@escardio.org)

Every even year in July (before the ESC Congress)

Every odd year in September (after the ESC Congress)

Activities of the Working Group during the year

Meetings

(For each meeting, please precise titles, dates, places, number of participants):

WG Annual Meeting(s):

1. New Trends in Cardiovascular Drug Therapy, June 7-8, 2013, Rome, Italy
The 1st WG Annual Meeting (New Trends in Cardiovascular Drug Therapy) was held in Rome, Italy, with 156 attendees, despite a relatively short time for preparations. The congress was a major success. The scientific program was well accepted, including poster presentations.

Endorsed Meetings:

2. CardioVascular Clinical Trialists Forum (CVCT), November 30 - December 1, 2012, Paris, France: 42 countries participated in CVCT 2012, which hosted over 430 participants onsite in Paris and over 400 additional participants through live streaming.

Position Papers Submitted by the Working Group

1. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis: Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-13, 1713a-1713b. Epub 2013 Feb 20.

Guideline participation

1. Arterial hypertension – Luis Ruilope, Faiez Zannad
2. CV prevention - Faiez Zannad
3. Heart failure – Faiez Zannad
4. Non-cardiac surgery - CV assessment and management – Keld Kjeldsen

Journal Affiliation

The journal "Fundamental and Clinical Pharmacology" is endorsed by the WG. FCP has an impact factor of 3.1.

A new dedicated WG journal has been approved (see below – next year's activities)

Sessions

Please complete and return to your Working Groups Officer / Coordinator (jpena@escardio.org / cgomez@escardio.org)

Every **even year** in **July** (before the ESC Congress)

Every **odd year** in **September** (after the ESC Congress)

Six WG sessions were accepted and presented at the scientific program of the ESC 2013 main congress in Amsterdam and were well attended.

1. Symposium: The heart and the gut. The use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
2. Symposium: Underutilisation of novel antiplatelet agents. What went wrong?
3. Symposium: Time for reappraisal of diuretics?
4. Debate Session: Making sense of clinical trials
5. Clinical Seminar: Controversies in interpreting clinical trials
6. Symposium: Drug interactions: what the cardiologist should know Proposed by WG3 (in collaboration with the Council for Cardiology Practice).

Activities of the Working Group for the coming year

Meetings

1. WG Annual Congress

The Second Annual Meeting of the WG - New Trends in Cardiovascular Drug Therapy - will take place on May 30-31, 2014 in Rome, Italy.

At this 2nd meeting, there will be a "reach out program" to more international participants, such as display of the meeting on the ESC homepage, regular updates in the web and by email, earlier advertisement, approach of local communities / institutions / companies by the WG members and the organizers to bring more participants.

2. Endorsed Meetings

- a. CVCT, Paris, Dec 2013

- b. Resistant Hypertension Course, February 20-22 2014, Berlin, Germany

3. Other Meetings

Additional scientific meetings as well as a position paper meeting and ad hoc meetings are in preparation

- a. Position paper meeting, Dec 5, 2013, Paris, France

- b. Strategy planning meeting, March 2014

- c. World Congress of Cardiology, May 4-7, 2014, Melbourne, Australia

10 sessions have been proposed by the WG. There has been no final decision yet.

- d. Extraordinary nucleus meeting at WG 2nd annual congress, May 2014, Rome Italy

Journals and Textbook

Please complete and return to your Working Groups Officer / Coordinator (jpena@escardio.org / cgomez@escardio.org)

Every **even year** in **July** (before the ESC Congress)

Every **odd year** in **September** (after the ESC Congress)

1. There has been formal approval for a new journal by the WG:
"European Heart Journal - Cardiovascular Pharmacology and Drug Therapy"
The journal will initially aim at 4 issues per year, and will be published by Oxford publishers
2. Fundamental and Clinical Pharmacology is endorsed by the WG. FCP has an impact factor of 3.1.
3. An ESC Textbook of Cardiovascular Pharmacology and Drug Therapy is in planning discussions. A book format together with an internet based/tablet format is a possibility, possibly with symbiosis between journal and textbook.

Position Papers

A number of position papers are in preparation or being planned:

In preparation

1. Optimum plasma-potassium and how to ensure it.
The proposal will be resubmitted to EHJ with practical information on diuretics and clinical relevance. Responsible author Keld Kjeldsen
2. Gender differences in cardiovascular pharmacology.
Paper has been drafted and will be submitted to EHJ. Responsible author Giuseppe Rosano

Planned Position Papers

3. NSAIDS – a cardiology perspective.
To be submitted to ESC. Responsible: Christian Torp-Pedersen
4. Management of patients with high LDL cholesterol and muscle pain on statin therapy
To be submitted to ESC. Responsible author: Heinz Drexel
5. Diagnosis and management of orthostatic hypotension.
Possible PP, to be submitted by Atul Pathak

Webpage

Webpage will be expanded to promote educational resources in keeping with ESC objectives.
Responsible: Harald Schmidt

Other projects

1. Active Participation with 11 proposals for scientific sessions for the 2014 ESC Congress:
 - i. Pharmacotherapy associated sudden death
 - ii. Challenges in cardiovascular drug therapy of coronary artery disease
 - iii. CV safety trials on anti-diabetic drugs: why bother?
 - iv. Strategy trials: important or impossible?

Please complete and return to your Working Groups Officer / Coordinator (jpena@escardio.org / cgomez@escardio.org)

Every **even year** in **July** (before the ESC Congress)

Every **odd year** in **September** (after the ESC Congress)

- v. Trials versus registries
- vi. New oral anticoagulants in clinical practice
- vii. Some issues for antiplatelet therapy in myocardial infarction
- viii. Challenges in use of New Anti-thrombotic drugs
- ix. General Surgery and cardiovascular drugs - benefits and risks
- x. Important interactions-what the cardiologist should know
- xi. Messages from recent trials in ACS: different perspective

Participation in ESC Clinical Guidelines production 2013-2014

1. Pulmonary embolism – Stefan Agewall (reviewer)

Prepare your budget for 2014-2015 (see sample)

Estimated Income:

ESC support to Extraordinary Nucleus Meeting, June 2014, Rome, Italy: 10.000 EURO

ESC support to Position Paper Meeting, December 2014, Paris, France: 10.000 EURO

Revenue from New Trends in Cardiovascular Drug Therapy 2014, Rome, Italy: 5.000 EURO

Revenue from CVCT 2014, Paris, France: 5.000 EURO

Estimated Expenses:

Strategy Meeting, spring 2014, Jerusalem, Israel: 10.000 EURO

Extraordinary Nucleus Meeting, June 2014, Rome, Italy: 10.000 EURO

Position Paper Meeting, December 2014, Paris, France: 10.000 EURO